In this Issue
- Upcoming Trial Readouts to Watch
- Lykos Prioritises Preparing for Resubmission Over Formal Dispute
- Bogenschutz Scores $3.8m NIAAA Grant for Psilocybin in Alcohol Use Disorder Study
- FDA Issues Decentralised Clinical Trials Guidance
- New Mental Health Parity Regs Come Into Force in January 2025
- More Headlines from Cybin, Bright Minds Biosciences, Richard Branson, Psychedelic Industry UK, Incannex, Big Health, Lophora, and others.
***
Upcoming Trial Readouts to Watch
As the news cycle becomes less consumed by Lykos (though, there is a short piece below), we’re looking ahead to upcoming sponsored psychedelic trial readouts slated for the next two or three quarters. Here is a selection to look out for…
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
